Biodistribution and Pharmacokinetics of Colon-specific HPMA Copolymer--9-aminocamptothecin Conjugate in Mice

Overview

Journal J Control Release

Specialty Pharmacology

Date 2006 Dec 8

PMID 17150276

Citations 8

Authors

Song-Qi Gao

Zheng-Rong Lu

Pavla Kopeckova

Jindrich Kopecek

Affiliations

Soon will be listed here.

Abstract

A water soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-9-aminocamptothecin (9-AC) conjugate was designed for oral colon-specific drug delivery in the treatment of colon cancer. Comparative studies between the polymer conjugate and free drug have been performed to assess their biodistribution and pharmacokinetics in mice. After oral administration of equal doses of the polymer conjugate or free 9-AC, the drug concentrations in major organs at fixed time points were determined using an HPLC-fluorescence assay. Only 2+/-1% of 9-AC released from the polymer conjugate was detected in the small intestine (SI), and the mean peak concentration of free 9-AC was 45-fold higher than that from released drug. Colon-specific release of 9-AC produced high local concentrations. The mean peak concentration of released 9-AC in cecal contents, feces, cecal tissue, and colon tissue were, respectively, 3.2-fold, 3.5-fold, 2.2-fold and 1.6-fold higher than that using free 9-AC. In plasma, the high and sharp drug concentration profile from free drug was in contrast to the relatively low and flat pharmacokinetic profile obtained from drug released from the HPMA copolymer. There was no significant difference between released and free drug for the area under the concentration-time curve (AUC) and bioavailability values. As a consequence of the colon-specific release of unmodified 9-AC from the polymer conjugate, antitumor efficacy can be anticipated to be enhanced due to prolonged colon tumor exposure to higher and more localized drug concentrations.

Citing Articles

Hydrophilic biomaterials: From crosslinked and self-assembled hydrogels to polymer-drug conjugates and drug-free macromolecular therapeutics.

Kopecek J J Control Release. 2024; 373:1-22.

PMID: 38734315 PMC: 11384549. DOI: 10.1016/j.jconrel.2024.05.012.

Pharmacokinetic and Biodistribution Studies of HPMA Copolymer Conjugates in an Aseptic Implant Loosening Mouse Model.

Wei X, Li F, Zhao G, Chhonker Y, Averill C, Galdamez J Mol Pharm. 2017; 14(5):1418-1428.

PMID: 28343392 PMC: 5906048. DOI: 10.1021/acs.molpharmaceut.7b00045.

POLYMERIC BIOMATERIALS AND NANOMEDICINES.

Yang J, Kopecek J J Drug Deliv Sci Technol. 2015; 30(Pt B):318-330.

PMID: 26688694 PMC: 4681002. DOI: 10.1016/j.jddst.2015.05.012.

Design of smart HPMA copolymer-based nanomedicines.

Yang J, Kopecek J J Control Release. 2015; 240:9-23.

PMID: 26437260 PMC: 4819016. DOI: 10.1016/j.jconrel.2015.10.003.

Biological rationale for the design of polymeric anti-cancer nanomedicines.

Zhou Y, Kopecek J J Drug Target. 2012; 21(1):1-26.

PMID: 23009337 PMC: 4605218. DOI: 10.3109/1061186X.2012.723213.

References

Takimoto C . Why drugs fail: of mice and men revisited. Clin Cancer Res. 2001; 7(2):229-30. View

Wilding I . Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst. 2001; 17(6):557-620. View

De Jonge M, Punt C, Gelderblom A, Loos W, van Beurden V, Planting A . Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol. 1999; 17(7):2219-26. DOI: 10.1200/JCO.1999.17.7.2219. View

Lu Z, Gao S, Kopeckova P, Kopecek J . Synthesis of bioadhesive lectin-HPMA copolymer-cyclosporin conjugates. Bioconjug Chem. 2000; 11(1):3-7. DOI: 10.1021/bc990098a. View

Wroblewski S, Berenson M, Kopeckova P, Kopecek J . Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation, and diseases of human and rodent gastrointestinal tissues. J Biomed Mater Res. 2000; 51(3):329-42. DOI: 10.1002/1097-4636(20000905)51:3<329::aid-jbm6>3.0.co;2-0. View

Gupta E, Vyas V, Ahmed F, Sinko P, Cook T, Rubin E . Pharmacokinetics of orally administered camptothecins. Ann N Y Acad Sci. 2001; 922:195-204. DOI: 10.1111/j.1749-6632.2000.tb07038.x. View

Kirstein M, Houghton P, Cheshire P, Richmond L, Smith A, Hanna S . Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res. 2001; 7(2):358-66. View

Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N . Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release. 2006; 113(1):38-42. DOI: 10.1016/j.jconrel.2006.03.020. View

Haupt S, Zioni T, Gati I, Kleinstern J, Rubinstein A . Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. Eur J Pharm Sci. 2006; 28(3):204-11. DOI: 10.1016/j.ejps.2006.02.001. View

10.

Lalloo A, Chao P, Hu P, Stein S, Sinko P . Pharmacokinetic and pharmacodynamic evaluation of a novel in situ forming poly(ethylene glycol)-based hydrogel for the controlled delivery of the camptothecins. J Control Release. 2006; 112(3):333-42. DOI: 10.1016/j.jconrel.2006.03.002. View

11.

Gao S, Lu Z, Petri B, Kopeckova P, Kopecek J . Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J Control Release. 2005; 110(2):323-331. DOI: 10.1016/j.jconrel.2005.10.004. View

12.

Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y . A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J Control Release. 2005; 104(2):337-46. DOI: 10.1016/j.jconrel.2005.02.011. View

13.

KAMPFFMEYER H, KIESE M . FURTHER FACTORS AFFECTING THE HYDROXYLATION OF ANILINE AND SOME OF ITS DERIVATIVES BY LIVER MICROSOMES. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1964; 246:397-412. DOI: 10.1007/BF00245405. View

14.

Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S . A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res. 1995; 1(3):269-76. View

15.

Grossman S, Hochberg F, Fisher J, Chen T, Kim L, Gregory R . Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol. 1998; 42(2):118-26. DOI: 10.1007/s002800050794. View

16.

Mani S, Iyer L, Janisch L, Wang X, Fleming G, Schilsky R . Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7. DOI: 10.1007/s002800050789. View

17.

Rubinstein A . Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst. 1995; 12(2-3):101-49. DOI: 10.1615/critrevtherdrugcarriersyst.v12.i2-3.10. View

18.

van den Mooter G, Maris B, Samyn C, Augustijns P, Kinget R . Use of azo polymers for colon-specific drug delivery. J Pharm Sci. 1998; 86(12):1321-7. DOI: 10.1021/js9702630. View

19.

Gerrits C, De Jonge M, Schellens J, Stoter G, Verweij J . Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer. 1997; 76(7):952-62. PMC: 2228255. DOI: 10.1038/bjc.1997.491. View

20.

May R, Tomaszewski J, Osborn B, Murphy M, Page J, Parchment R . Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol. 1997; 39(5):467-72. DOI: 10.1007/s002800050600. View